04:36 AM EDT, 06/24/2024 (MT Newswires) -- Takeda (TAK) said Monday that its drug Livtencity has been approved by the Japan's Ministry of Health, Labour and Welfare for the treatment of cytomegalovirus disease that is resistant to existing therapies in patients with transplanted organs.

The drug, also known as maribavir, was approved following a phase 3 trial involving 352 patients with either transplanted stem cells or organ transplants that met its primary endpoint and showed "statistically significant improvement" for those treated with the drug versus those treated with other therapies, the company said.

Cytomegalovirus infections can lead to hospitalization or cause organ rejection when not properly treated.

Price: 12.71, Change: +0.11, Percent Change: +0.87